Shan-Lu Liu earns Ohio State’s top faculty honor for 2026: full analysis

Shan-Lu Liu, MD, PhD, has been named a 2026 Distinguished University Professor at The Ohio State University, a designation Ohio State describes as its highest faculty honor. The April 20 announcement from the College of Veterinary Medicine positions the award as recognition not just for a long publication record, but for a body of virology research with practical influence on public health, including work the university says helped inform FDA decisions on COVID-19 vaccine formulations. (vet.osu.edu)

Liu has been at Ohio State since 2016, where he built a virology program with relevance across human and animal health. His research portfolio has focused on how viruses enter cells, evade host defenses, and adapt under immune pressure. Ohio State credits his lab with advances involving interferon-induced transmembrane, or IFITM, proteins, as well as TIM and SERINC family proteins, work that has broadened understanding of innate antiviral defense and viral pathogenesis. Those themes have made his lab particularly visible during the COVID-19 era, when questions about immune escape, variant behavior, and vaccine design moved from basic science into regulatory and clinical decision-making. (vet.osu.edu)

The university’s profile of Liu also points to the breadth of his leadership roles. In addition to his faculty appointment in the College of Veterinary Medicine, he serves as associate director of Ohio State’s Center for Retrovirus Research and co-directs the Viruses and Emerging Pathogens Program within the Infectious Diseases Institute. Ohio State says he helped secure a major NIH grant for that program in 2020, and internal newsletters show his research enterprise has also been tied to later federal support, including zoonotic transmission work. That broader funding and infrastructure context matters because it shows this is an award for a scientist whose influence extends across institutional strategy, not only individual discovery. (vet.osu.edu)

Ohio State and affiliated materials also frame Liu as a nationally visible figure in virology. He was elected a fellow of the American Academy of Microbiology in 2018 and a fellow of the American Association for the Advancement of Science in 2020, according to the university. His faculty page lists him as 2025-2026 president of the American Society for Virology, and ASM recently referenced ASV as one of its active virology-society partners, reinforcing that current leadership role. (vet.osu.edu)

Direct outside reaction to this specific award appears limited so far, but Ohio State Dean Rustin Moore called Liu’s work “real-world impact on global public health” in the university announcement. That assessment is consistent with Liu’s publication and commentary trail around SARS-CoV-2, including Ohio State reporting on his group’s work on variant neutralization and lower-respiratory-cell infectivity. While the university’s statement that his findings informed FDA vaccine formulation decisions is difficult to fully trace to a single regulatory filing from public search results alone, Ohio State’s own research summaries and center newsletters repeatedly connect his lab’s antibody and variant studies to discussions around BA.5-era and later vaccine updates. That makes it reasonable to view the claim as an institutional summary of influence rather than a reference to a single decisive FDA action. (vet.osu.edu)

Why it matters: For veterinary professionals, this is a reminder that colleges of veterinary medicine are central players in translational infectious disease research. Liu’s work sits squarely in the comparative space where animal models, host-pathogen biology, zoonotic risk, and immunology overlap. In practice, that means veterinary institutions are helping generate the science that informs vaccine updates, outbreak response, and preparedness for emerging pathogens affecting both animals and people. For clinicians and researchers alike, the recognition also signals continued prestige for veterinary biosciences at a time when funders and policymakers remain focused on One Health and pandemic resilience. (vet.osu.edu)

What to watch: The next signal will be whether Ohio State uses this recognition to further expand Liu’s platform through new grants, cross-college collaborations, or higher-profile emerging pathogen initiatives. It will also be worth watching how his national leadership roles, including with the American Society for Virology, shape Ohio State’s visibility in conversations around zoonoses, vaccine strategy, and research priorities in 2026 and beyond. (vet.osu.edu)